CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Novel Biologics  /  Nimotuzumab

NOVEL PIPELINE

Nimotuzumab

India’s first indigenously produced novel monoclonal antibody for head and neck cancer

Launched in 2006, Nimotuzumab or BIOMAb EGFR targets the epidermal growth factor receptor (EGFR) present on the cell surface. The binding of certain growth factors to this receptor starts a series of events that are essential for cell growth, differentiation, and survival. In cancerous cells, there is an overexpression of EGFR leading to uncontrolled cell growth, proliferation, survival and creation of new blood vessels. A very high level of EGFR is seen in many solid tumours, caused by poor treatment outcomes. Based on the experience of thousands of patients, BIOMAb EGFR is the only monoclonal antibody of its class that has rarely exhibited any severe skin rashes. Efficacy without associated toxicities is the unique feature that differentiates BIOMAb EGFR from other targeted therapies against EGFR.

null

FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
PRESS RELEASES
Share